

# 7 October 2015

CMP: Rs.41.0 Industry: Other Agricultural Products BSE group: M

#### **Promoters**


i. Tarun Chauhan

ii. Madhu Anand

#### **Key Data**

BSE	535217
ISIN	INE507001025
Face Value (Rs.)	1.0
Mkt Cap (Rs. mn)	6543.6
Current P/E	38.0
Current P/BV	2.2
52 week low-high	75.75-28.9
30 days avg daily trading volume	-
Equity capital (Rs mn)	159.6
Net worth (Rs mn)	296.3

# Shareholding Pattern (%)



## Click here for: Initiation Report

Write to us at: equity.research@outlook.com

## **Company business**

HPC Biosciences Limited (HPCBL) is engaged in agriculture operations of cultivation, processing and distribution of agriculture commodities like wheat, paddy, sugar cane, fruits, vegetables and flowers. The company has also entered into the operations of wood plantation, wherein it is planting Bamboos, Kadam, Poplar and Eucalyptus.

#### **Updates**

The company has shifted its registered office to Flat No. 6, third floor, Office no. 304, IP Extension, near Ajanta Apartment, Delhi-110092 with effect from 8 January 2015. The company secretary, Ms. Avni Garg resigned with effect from 31 January 2015. The Equity shares of the company were split from a Face Value of Rs. 10.0 each to Re.1.0 each with 23 February 2015 as the record date. The company received shareholder approval by way of a Postal Ballot to migrate the Company's present listing from SME platform of the BSE Ltd. to the Main Board of BSE Ltd. Ms. Sakshi Saxena resigned as an Independent Director with effect from 13 July 2015.

#### **Financials**


Particulars (Rs in mn)	Six Months ended Mar '15	Six Months ended Mar'14	% Change <sup>1</sup>	Six Months ended Sep'14	% Change <sup>2</sup>
Total income	17.6	26.2	(32.9%)	15.05	16.7%
Total operating expenditure	7.3	9.5	(22.7%)	3.6	105.4%
EBIDTA	10.2	16.7	(38.7%)	11.5	(10.9%)
EBIDTA margin	58.2%	63.7%	-	76.3%	-
РВТ	2.9	9.5	(69.5%)	4.7	(37.8%)
PAT	2.6	9.4	(72.3%)	4.5	(42.0%)
PAT margin	14.8%	35.8%	-	29.8%	-
Cash accruals	9.9	16.6	(40.3%)	11.3	(12.2%)
EPS	0.0	0.6	-	0.3	-

<sup>1</sup> compared to corresponding quarter in the previous year <sup>2</sup> sequential comparisons Source: Company <sup>2</sup>

## **Financial Performance**

In the six months ended 31 March 2015, the total income of the company increased by 16.7% to Rs.17.6 mn over the six months ended 30 September 2014. The total income of the company decreased by 32.9% over the corresponding period of the previous year. Operating expenses increased as a percentage of total income resulting in a decline in EBIDTA margin. The Company reported net profit of Rs. 2.6 mn compared to Rs. 9.4 mn in the corresponding period of previous year.

# **Share Price Performance**





# **HPC Biosciences Limited**

### **Financials**

P&L (Rs. mn)	FY12	FY13	FY14
Total income	36.8	50.3	33.1
EBITDA	31.8	43.1	26.2
EBITDA margin	86.4%	85.6%	79.2%
Depreciation	1.3	13.3	13.6
EBIT	30.5	29.8	12.6
Interest	0.0	0.0	0.0
РВТ	30.5	29.8	12.6
Тах	0.0	0.0	0.2
РАТ	30.5	29.8	12.4
PAT Margin	82.9%	59.2%	37.5%
Dividend	-	-	-
Dividend Payout	-	-	-

Balance Sheet (Rs. mn)	FY12	FY13	FY14
Share Capital	17.5	159.6	159.6
Share application money, warrants	0.0	0.0	0.0
Reserves & Surplus	30.5	117.2	129.6
Net worth	48.0	276.8	289.2
Borrowings	0.0	1.0	3.8
Current Liabilities and provisions	0.0	0.4	0.9
Net deferred tax Liabilities	0.0	0.0	0.0
Total liabilities	48.0	278.3	293.9
Fixed assets	11.0	105.7	95.3
Investments	0.0	24.9	27.8
Loans and Advances		36.9	36.9
Current Assets	37.0	110.8	133.9
Total assets	48.0	278.3	293.9
Cash Flow (Rs.mn)	FY12	FY13	FY14
РВТ	30.5	29.8	12.6
CF from Operation	20.2	34.0	40.0
CF from Investment	(36.2)	(228.1)	(45.3)
CF from Financing	17.0	200.0	2.8
Inc/(dec) Cash	1.0	5.9	(2.5)
Closing Balance	1.1	7.0	4.5

#### Disclaimer

The information contained herein is from publicly available data or other sources believed to be reliable, but we do not represent that it is accurate or complete and it should not be relied on as such. Our company shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This document is provided for assistance only and is not intended to be and must not alone be taken as the basis for any investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigation as it deems necessary to arrive at an independent evaluation which may affect their investment in the securities of companies referred to in this document (including the merits and risks involved). The discussions or views expressed may not be suitable for all investors. This information is strictly confidential and is being furnished to you solely for your information.